Cetuximab is not indicated in EGFR expression colorectal cancer with a Ras‐mutant due to treatment‐related toxicity; EGFR amplification co‐occurred with an NRAS (p.G12S) mutation in a single tumor. Here, NRAS is linked to neoplasm.